Scinai Immunotherapeutics
SCNI
6 hedge funds and large institutions have $60.9K invested in Scinai Immunotherapeutics in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
3.13% less ownership
Funds ownership: 7.94% → 4.81% (-3.1%)
66% less capital invested
Capital invested by funds: $181K → $60.9K (-$120K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$29.6K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$25.6K |
| 3 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$1.74K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$122 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YAG
Yorkville Advisors Global
Mountainside,
New Jersey
|
-$95.8K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$22.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$21K |
| 4 |
Morgan Stanley
New York
|
-$17 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $36.2K | +$29.6K | +17,031 | +147% |
|
|
TSS
2
Two Sigma Securities
New York
| $18.6K | +$25.6K | +14,696 | New |
|
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $4.49K | +$122 | +70 | +2% |
|
|
4
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $1.26K | +$1.74K | +1,000 | New |
|
|
5
Morgan Stanley
New York
| $310 | -$17 | -10 | -4% |
|
|
6
UBS Group
Zurich,
Switzerland
| $10 | -$21K | -12,048 | -100% |
|
|
YAG
7
Yorkville Advisors Global
Mountainside,
New Jersey
| – | -$95.8K | -42,000 | Closed |
|
|
8
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$22.9K | -10,000 | Closed |
|
SCNI Hedge Fund Activity: Q3 2025 in Review
6 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2025, worth a combined $60.9K — down 66% from $181K a quarter earlier.
Fund positioning in SCNI was balanced in Q3 2025: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $29.6K. The largest seller was Yorkville Advisors Global, exiting entirely with an estimated $95.8K sold.
- 6 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $60.9K of Scinai Immunotherapeutics stock for Q3 2025, down 66% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q3 2025 and 2 closed out, a net change of 0 holders.
- The largest Scinai Immunotherapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $29.6K added.
- The largest Scinai Immunotherapeutics seller in Q3 2025 was Yorkville Advisors Global, an estimated $95.8K sold.
Based on aggregated 13F filings for Q3 2025.